Drug utilisation profile in the neonatal unit of a university hospital: a prospective observational study in Brazil
- 201 Downloads
Background Advances in neonatology have contributed to changes in the drug utilisation profile in neonates, both in the number of drugs and the pharmacotherapeutic groups. Objective To analyse drug use in the neonatal care unit of a teaching hospital in Brazil and to evaluate the associations among perinatal, clinical care and drug use data. Setting The neonatal care unit of a teaching hospital in Brazil. Methods A prospective observational study was conducted. Perinatal, clinical care and pharmacotherapy data were collected from the patients’ medical records. Labelling information regarding neonatal use was analysed for prescribed drugs. The data were analysed using univariate descriptive statistics and quasi-Poisson regression. Main outcome measure Frequency of drug use by gestational age. Results The study included 187 patients; 157 (84.0 %) received drugs. The mean gestational age was 35.8 weeks. The mean number of drugs prescribed per patient was 6.4. The number of drugs used was inversely correlated to gestational age and birth weight. The most commonly prescribed drugs belonged to the following anatomical therapeutic chemical groups: nervous system drugs, anti-infectives for systemic use, and alimentary tract and metabolism drugs. Information regarding neonatal use was given in the labelling of only 20.5 % of the prescribed drugs. Of these, only 9.5 % had information specific for preterm infants. Conclusions Drug administration to neonates is frequently and inversely correlated to gestational age and birth weight. Neonates are exposed to different therapeutic classes, reflecting scientific advances in neonatology. In Brazil, the percentage of drugs with neonate-specific labelling information is low. Consequently, there is an evident need for efforts to guarantee effective and safe pharmacotherapy for neonates.
KeywordsBrazil Drug utilisation Infant Intensive care units Neonatal Neonatology Newborn Pharmacoepidemiology
This research was supported by a grant from Pró-Reitoria de Pesquisa da Universidade Federal de Minas Gerais for the Qualitative Improvement Program of Scientific Production.
Conflicts of interest
The authors declare no conflict of interest.
- 1.Flor-de-Lima F, Rocha G, Guimarães H. Impact of changes in perinatal care on neonatal respiratory outcome and survival of preterm newborns: an overview of 15 years. Crit Care Res Pract. 2012; 1–7.Google Scholar
- 10.Carvalho C, Ribeiro M, Bonilha M, Fernandes M Jr, Procianoy RS, Silveira R. Use of off-label and unlicensed drugs in the neonatal intensive care unit and its association with severity scores. J Pediatr. 2012;88(6):465–70.Google Scholar
- 12.World Health Organization. Recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths. Acta Obstet Gynecol Scand. 1977;56:247–53.Google Scholar
- 13.World Health Organization. Collaboration Centre for Drug Statistics Methodology. Anatomical-therapeutical-chemical (ATC) classification—index and guidelines. http://www.who.no/atcddd. Accessed 13 Aug 2014.
- 24.Cunha GSMF, Ribeiro JD. Maternal and neonatal factors affecting the incidence of bronchopulmonary dysplasia in very low birth weigth newborns. J Pediatr. 2003;79:550–6.Google Scholar
- 31.Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry B, Pulido T, Layton GR, Serdarevic-Pehar MA. Randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertensionclinical perspective. Circulation. 2012;125(2):324–34.PubMedCrossRefGoogle Scholar
- 32.Abman SH, Kinsella JP, Rosenzweig EB, Krishnan U, Kulik T, Mullen M, Wessel DL, Steinhorn R, Adatia I, Hanna B. Implications of the FDA warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Am J Respir Crit Care Med. 2012;187(6):572–5.PubMedCrossRefGoogle Scholar
- 35.National Institutes of Health (NIH). Best pharmaceuticals for children act (BPCA) priority list of needs in pediatric therapeutics. http://bpca.nichd.nih.gov/prioritization/status/documents/priority_list_10-26-2012.pdf. Accessed 13 Aug 2014.
- 40.Nahata MC. Lack of pediatric drug formulations. Pediatrics. 2009;104:607–9.Google Scholar